Background Cyclophosphamide and glucocorticoids have been the cornerstone of
remission-induction therapy for severe antineutrophil cytoplasmic antibody (ANCA) …

Objective B cells are likely to contribute to the pathogenesis of systemic lupus
erythematosus (SLE), and rituximab induces depletion of B cells. The Exploratory Phase II/III …

Objective To evaluate the efficacy and safety of rituximab in a randomized, double‐blind,
placebo‐controlled phase III trial in patients with lupus nephritis treated concomitantly with …

Background The 18-month efficacy of a single course of rituximab as compared with
conventional immunosuppression with cyclophosphamide followed by azathioprine in …

Objective Randomised trials of type I anti-CD20 antibodies rituximab and ocrelizumab failed
to show benefit in proliferative lupus nephritis (LN). We compared obinutuzumab, a …

Objective To investigate the efficacy and safety of ocrelizumab in patients with class III/IV
lupus nephritis (LN). Methods Patients were randomized 1: 1: 1 to receive placebo, 400 mg …

Objective To evaluate whether the classification of patients with anti-neutrophil cytoplasmic
antibody (ANCA)-associated vasculitis (AAV) according to ANCA type (anti-proteinase 3 …

Severe lupus nephritis is an aggressive disease that requires an aggressive approach to
treatment. Recent randomized clinical trials showed that mycophenolate mofetil compared …

Objectives To develop a Glucocorticoid Toxicity Index (GTI) to assess glucocorticoid (GC)-
related morbidity and GC-sparing ability of other therapies. Methods Nineteen experts on …

Granulomatosis with polyangiitis and microscopic polyangiitis are anti-neutrophil
cytoplasmic antibody-associated vasculitides (AAVs) that are prone to cycles of remission …